Infrequent CDKN2 mutation in human differentiated thyroid cancers

Molecular Carcinogenesis

Volumn 15, Issue 1, 1996, Pages 5-10

  Tung, William S ^a   Shevlin, Douglas W ^a   Bartsch, Detlef ^a   Norton, Jeffrey A ^a   Wells Jr , Samuel A ^a   Goodfellow, Paul J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8109 ^*  (United States)

Author keywords

CDKN2; Loss of heterozygosity; Thyroid neoplasms; Tumour suppressor genes

Indexed keywords

ANAPLASTIC CARCINOMA; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, FOLLICULAR; BASE SEQUENCE; CARCINOMA, PAPILLARY; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; DNA, NEOPLASM; HUMANS; MOLECULAR SEQUENCE DATA; POINT MUTATION; SEQUENCE DELETION; THYROID NEOPLASMS;

EID: 0030045908     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199601)15:1<5::AID-MC2>3.0.CO;2-K     Document Type: Article

References (29)

1. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
2. Kamb A, Gruis N, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types Science 264:436-440, 1994.
3. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma Cancer Res 54.3396-3397, 1994.
4. Zhou X, Tarmin L, Yin J, et al The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9:3737-3741, 1994.
5. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas Genes Chromosom Cancer, in press.
6. Hayashi N, Yoshihisa S, Tsuchiya E, Ogawa M, Nakamura Y Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430, 1994
7. Giani C, Finocchario G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54:6338-6339, 1994.
8. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55:20-23, 1995
9. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4044, 1994.
10. Ohta M, Nagai H, Shimizu M, et al Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I in melanoma. Cancer Res 54:5269-5272, 1994
11. ink4) in human breast carcinomas. Cancer Res 54:5262-5264, 1994.
12. Zhang S, Klein-Szanto AJP, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5063, 1994.
13. Peiffer SL, Bartsch D, Whelan AJ, Mutch DG, Herzog TJ, Goodfellow PJ. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog 13:210-212, 1995.
14. Ueki K, Rubio M, Ramesh V, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3:1841-1845, 1994
15. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55:224-227, 1995.
16. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164, 1989.
17. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 60:557-563, 1990.
18. Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression. Association with p53 gene mutations. Jpn J Cancer Res 84:526-531, 1993.
19. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 55:1922-1926, 1995.
20. Wright DK, Manos MM Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds), PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego, 1990, pp. 153-158
21. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994
22. INK4 function Nat Genet 10:114-116, 1995.
23. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma, Nature 305:779-784, 1983.
24. Spruck CH, Gonzalez-Zulueta M, Shibata A, et al. p16 in uncultured tumours. Nature 370:183-184, 1994.
25. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-416, 1994.
26. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers Nat Med 1:686-692, 1995.
27. Herrmann MA, Hay ID, Bartelt DH, et al Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest 88:1596-1604, 1991.
28. Matsuo K, Tang S, Fagin JA Allelotype of human thyroid tumors: Loss of chromosome 11q13 sequences in follicular neoplasms Mol Endocrinol 5:1873-1879, 1991.
29. Leight GS. Nodular goiter and benign and malignant neoplasms of the thyroid. In: Sabiston DC (ed), Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 14th ed. W. B. Saunders Co., Philadelphia, 1991, pp 579-590